<DOC>
	<DOCNO>NCT01671826</DOCNO>
	<brief_summary>Autologous stem cell transplantation remain gold standard treatment newly diagnose patient age 65 . Even though also regularly perform age 65 , data patient population . The investigator capture safety efficacy data setting .</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation Myeloma Patients Over 65 Years</brief_title>
	<detailed_description>Newly diagnose myeloma patient age 65 year treat follow way : Bortezomib ( VelcadeÂ® ) base induction treatment ( either Velcade Dexamethasone , Velcade Thalidomide Dexamethasone ( VTD ) Velcade Cyclophosphamide Dexamethasone ( VCD ) ) . After induction phase , patient least partial remission , collection peripheral blood stem cell ( PBSC ) do accord center practice . High dose melphalan ( 140 mg/m2 ) follow PBSC autologous transplantation perform . Three month post transplant , 2-3 cycle ( similar initial induction phase ) consolidation allow .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>newly diagnose MM , age 65 , measurable disease Patients le 65 and/or proceed autologous PBSC transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>Elderly Patients</keyword>
</DOC>